Circassia’s novel NIOX® products are used to assist asthma management around the world. We market the products directly in the United States and Germany and plan to expand our direct presence into a number of other countries. We also provide NIOX® through an international network of distributors.
Monitoring airway inflammation – monitoring asthma
Allergic airway inflammation is the major underlying cause of asthma. Measuring this inflammation can be expensive, invasive and time consuming, and tests such as those using induced sputum or airway biopsy are often not readily available.
Circassia’s point-of-care NIOX® products offer a straight forward alternative. NIOX® exploits the discovery that patients with allergic airway inflammation generally have higher than normal levels of nitric oxide in their exhaled breath. By measuring the concentration of this nitric oxide (the fractional exhaled nitric oxide or FeNO), clinicians can evaluate allergic airway inflammation in patients with underlying asthma.
As a result, NIOX® is used to improve asthma management by assisting in:
- determining responsiveness to inhaled corticosteroids
- tailoring inhaled steroid use
- monitoring treatment compliance
- reducing exacerbations.
Circassia’s NIOX VERO® offers significant improvements over the previous generation NIOX MINO®. It’s easy to use, portable and has a longer life span. In addition, it provides quicker test results using easy-to-replace sensors that are available for 100, 300, 500 or 1,000 individual tests. The product is approved in a number of countries and has recently been launched in several major markets including the US, EU, Japan and China.
US Use and Risks Statement
NIOX VERO® measures Nitric Oxide (NO) in human breath. Nitric Oxide is frequently increased in some inflammatory processes such as asthma. The fractional NO concentration in expired breath (FeNO), can be measured by NIOX VERO according to guidelines for NO measurement established by the American Thoracic Society.
Measurement of FeNO by NIOX VERO is a quantitative, non-invasive, simple and safe method to measure the decrease in FeNO concentration in asthma patients that often occurs after treatment with anti-inflammatory pharmacological therapy, as an indication of the therapeutic effect in patients with elevated FeNO levels. NIOX VERO is suitable for children, approximately 7 – 17 years, and adults 18 years and older.
FeNO measurements provide the physician with means of evaluating an asthma patient’s response to anti-inflammatory therapy, as an adjunct to the established clinical and laboratory assessments in asthma. The NIOX VERO is intended for prescription use and should only be used as directed in the NIOX VERO User Manual by trained healthcare professionals. NIOX VERO cannot be used with infants or by children approximately under the age of 7, as measurement requires patient cooperation. NIOX VERO should not be used in critical care, emergency care or in anaesthesiology.